TWST earnings call summary

Prepared Highlights

• Total revenue $110.7M, up 19.3% YoY, 13th consecutive quarter of sequential growth (CFO).
• DNA synthesis & Protein Solutions $53.3M, +28% YoY, driven by AI-enabled drug discovery (CFO).
• NGS applications $57.4M, +12% YoY and +9% sequentially, driven by top accounts (CFO).
• Gross margin 51.6%, +200 bps YoY (CFO).
• Adjusted EBITDA loss $13.3M, improvement of ~$1.5M YoY (CFO).
• Operating expenses $95.8M (ex-cost of revenue & litigation), vs $87.6M prior year (CFO).
• CapEx $7.9M for manufacturing automation (CFO).
• Cash & short-term investments $171.7M, down from $197.9M at Dec 31, 2025 (CFO).
• RPO/backlog not stated.
• Official guidance: FY2026 total revenue $442M–$447M (17%–19% growth); Q3 FY2026 revenue $114M–$115M (~19% YoY growth at midpoint); adjusted EBITDA breakeven in Q4 FY2026 (CFO).
• Litigation: $7.2M booked for securities class action settlement, expected to be covered by insurance (CFO).

Mgmt quotes:

• "Twist delivered another strong quarter and extended our track record of consistent execution, posting our 13th quarter of sequential revenue growth." (CEO)
• "Our platform's ability to run large complex sequence sets in parallel accelerates every stage of that workflow." (CEO)
• "We have an algorithm embedded in our e-commerce system to inform a customer immediately if they have uploaded a sequence that may be difficult to manufacture." (President & COO)
• "We will soon take a full range of sequences across length and complexity, driving towards accepting approximately 99.5% of clonal genes and 99.9% of all DNA products more broadly." (President & COO)
• "We have delivered 13 consecutive quarters of sequential revenue growth, expanding gross margins above 50% and maintain a clear path to adjusted EBITDA breakeven in fiscal 2026." (CEO)

Prepared Metrics

Q&A Batch (1-5 of 11)

Q1 — Steven Etoch

• Topic: AI驱动工作流表现与财报指引更新
• Key points:
  • SPS同比增长28%
  • 治疗类别单季度突破4000万美元
  • AI将序列需求从个位数提升至数千个
• Mgmt stance: 看涨，因AI推动菜单整体需求与数据 upsell

Q2 — Vijay Kumar

• Topic: AI相关项目对55%增长的贡献及可持续性
• Key points:
  • Q2增长55%，AI为主要驱动
  • 从2025年少数账户扩展至数十个账户
  • 不再按产品组单独指引，全业务广基增长
• Mgmt stance: 看涨，因订单簿与NGS业务信心支撑全年上调

Q3 — Douglas Schenkel

• Topic: 学术与政府市场及毛利率走势
• Key points:
  • A&G市场趋势待确认
  • 毛利率环比小幅下降，略低于模型预期
  • Express基因促销影响夏季后将逐步消退
• Mgmt stance: 中性，等待市场稳定信号

Q4 — Adam Laponis

• Topic: IgG表征投资与全年毛利率指引
• Key points:
  • 2026全年毛利率指引维持52%或以上
  • 增量收入向毛利率回落75%-80%
  • 投资用于支持加速需求与自动化
• Mgmt stance: 看涨，因投资带来高ROI与产能扩张

Q5 — Luke Sergott

• Topic: 自动化工作流CapEx与AI项目数据转化
• Key points:
  • 新设施后端自动化CapEx有限，无需新建晶圆厂规模
  • 2025年Q4的2500万美元AI订单已于Q1基本交付
  • 数据交付周期15-20天
• Mgmt stance: 看涨，因自动化提升产能且AI订单快速转化

Q&A Batch (6-10 of 11)

Q6 — Subhalaxmi Nambi

• Topic: Full-year revenue guidance raise drivers
• Key points:
  • Full-year guidance raised by more than Q2 beat; back-half improvements primarily from NGS, but DSPS is the strength of the raise.
  • Sequentially, DSPS not expected to decline; overall revenue increases at a more modest rate.
  • Upside opportunity depends on pace of new DSS customers.
• Mgmt stance: Neutral – guidance raise is specific to DSPS, but pace of customer acquisition is the key variable.

Q7 — Matthew Larew

• Topic: Complex DNA offering timeline and capabilities
• Key points:
  • Twist currently accepts vast majority of sequences; a few percentage points of complex sequences are declined, sometimes causing loss of entire orders.
  • New offering targets emerging needs in nucleic acid therapeutics, plant engineering, and AI; leverages existing platform with up to ~$1 billion per (unit unclear) for quality, speed, and scale.
  • Early access starting with a few customers; capability ramp-up expected over coming quarters.
• Mgmt stance: Bullish – positions as a one-stop shop with best-in-class quality, speed, and customer support; scaling in coming quarters.

Q8 — Catherine Ramsey

• Topic: Adjusted EBITDA breakeven and margin leverage beyond Q4
• Key points:
  • On track for adjusted EBITDA breakeven in Q4; currently balancing investment to maximize revenue growth acceleration.
  • Future optionality exists; focus on not going backwards and sustaining accelerated growth.
  • More details to be discussed at upcoming Investor Day.
• Mgmt stance: Neutral – laser-focused on near-term breakeven and growth; future margin leverage will be addressed later.

Q9 — Unknown Analyst

• Topic: Gene revenue growth and AI-driven demand
• Key points:
  • Gene revenue growth observed; specific numbers not shared to avoid disclosing too much to competitors.
  • Growth is “more” than prior period, driven by internal data generation for sale.
  • AI demand shift: initial model-building boluses are now smaller but more frequent orders as customers “turn the crank.”
• Mgmt stance: Bullish – pleased with returning customers and sustained AI-driven demand; orders are smaller but more frequent.

Q10 — Brendan Smith

• Topic: AI revenue run rate and breakdown for 2026
• Key points:
  • AI discovery revenue falls within therapeutics segment; outsized growth vs. business average is predominantly AI discovery work.
  • Hard to precisely distinguish between training vs. model-building work; strong confidence that vast majority of growth in therapeutics is AI-related.
  • No specific breakdown provided for oligos vs. IgG vs. analytical data.
• Mgmt stance: Neutral – confident in AI contribution but lacks granular breakdown; run rate not quantified.

Q&A Batch (11-11 of 11)

Q11 — Tom DeBourcy

• Topic: 诊断业务及NGS增长趋势与全年展望
• Key points:
  • 第四季度NGS业务自身实现了至少1%的增长。
  • 管理层重申优先目标是整体营收增长、毛利率维持在50%以上以及实现调整后EBITDA盈亏平衡。
  • NGS应用端的文库制备产品组合正在推动增长，液态活检和MRD（微小残留病灶）客户正在上量。
  • 本季度总营收为1.107亿美元，而过去全年营收曾仅为1900万美元。
• Mgmt stance: 看涨。管理层对NGS业务充满信心，认为NGS与合成生物学业务将交替贡献高增长，并强调公司在生命科学工具行业中持续展现出独特的增长能力。